Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityLiabilities and Shareholders EquityOther Non-Current LiabilitiesPayablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Greenwich LifeSciences (GLSI) Accounts Payables (2019 - 2025)

Greenwich LifeSciences filings provide 7 years of Accounts Payables readings, the most recent being $220845.0 for Q3 2025.

  • Quarterly Accounts Payables fell 71.5% to $220845.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $220845.0 through Sep 2025, down 71.5% year-over-year, with the annual reading at $220845.0 for FY2024, 0.0% changed from the prior year.
  • Accounts Payables hit $220845.0 in Q3 2025 for Greenwich LifeSciences, roughly flat from $220845.0 in the prior quarter.
  • Across five years, Accounts Payables topped out at $1.3 million in Q2 2024 and bottomed at $220845.0 in Q4 2021.
  • Average Accounts Payables over 5 years is $361595.3, with a median of $220845.0 recorded in 2021.
  • The largest annual shift saw Accounts Payables surged 504.6% in 2024 before it tumbled 83.46% in 2025.
  • Greenwich LifeSciences' Accounts Payables stood at $220845.0 in 2021, then changed by 0.0% to $220845.0 in 2022, then changed by 0.0% to $220845.0 in 2023, then changed by 0.0% to $220845.0 in 2024, then changed by 0.0% to $220845.0 in 2025.
  • Per Business Quant, the three most recent readings for GLSI's Accounts Payables are $220845.0 (Q3 2025), $220845.0 (Q2 2025), and $220845.0 (Q1 2025).